Actinium Pharmaceuticals, Inc. Their mission is to provide precision radiation treatment to patients with high unmet needs. They focus on utilizing radiotherapies for targeted conditioning, which selectively eliminates disease or cancer cells and certain immune cells before bone marrow transplant, gene therapy, or adoptive cell therapy.

Among their impressive pipeline, their lead product candidate, I-131 apamistamab (Iomab-B), has been extensively studied in over 400 patients and is currently in Phase 3 clinical trials for elderly relapsed or refractory acute myeloid leukemia (AML) patients. Actinium also has promising products such as Iomab-ACT, Actimab-A, and a wide range of collaborative research partnerships. With their industry-leading technology and expertise, Actinium Pharmaceuticals is revolutionizing cancer treatment.

Stay connected with their email sign-up to receive the latest news, events, and updates